advanced search
search help


ipHandbook Blog

Your source for expert commentary on IP management issues.
Go to the blog



Editor-in-Chief,   Anatole Krattiger

Editorial Board

Concept Foundation


Fiocruz, Brazil

bioDevelopments-   Institute

MAHONEY, Richard T

MAHONEY, Richard T Photograph Richard T. Mahoney is Director, Vaccine Access, for the Pediatric Dengue Vaccine Initiative, a program of the International Vaccine Institute (IVI) in Korea. Previously, he was Research Professor in the School of Life Sciences and in the Biodesign Institute of Arizona State University. As a consultant to the Rockefeller Foundation, he played a lead role in the consultative process that led to the formation of MIHR. Previously, he was responsible for institutional development in the establishment and launching of the IVI in Seoul, Korea. In this role, he was responsible for cultivating relations with vaccine manufacturers and managing intellectual property, among other things. Dr. Mahoney has had a long career in public health and is known for his work with the International Task Force on Hepatitis B Immunization, accomplished while he was with the Program for Appropriate Technology in Health (PATH). Before co-founding and joining PATH, he was a Program Officer in Population with the Ford Foundation. He oversaw the development and implementation of IP management policies for the Ford Foundation, PATH, and IVI. Prof. Mahoney continues to write on policy and economic research.

Contributions       Show All AbstractsShow All Abstracts

Show AbstractAbstract Agreements: A Review of Essential Tools of IP Management

Show AbstractAbstract Building Product Innovation Capability in Health

Show AbstractAbstract Developing Countries and TRIPS: What Next?

Show AbstractAbstract Ensuring Global Access through Effective IP Management: Strategies of Product-Development Partnerships

Show AbstractAbstract Negotiating an Agreement: Skills, Tactics, and Best Practices

Show AbstractAbstract The Role of IP Management in Health and Agricultural Innovation

Show AbstractAbstract Specific IP Issues with Molecular Pharming: Case Study of Plant-Derived Vaccines

Message from Editorial Board